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Pulmonary Drug Delivery
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Abstract
Pulmonary administration is an effective method for treating lung and other
diseases. Drugs can be transported directly to the lung by the pulmonary drug
delivery system (PDDS). PDDS has the advantages of maintained local drug con-
centration, reduced side effects, controllable drug release, promoted drug absorp-
tion, prolonged drug action time, and improved patient compliance. Polymers have
been extensively utilized to prepare novel PDDS. Among these polymers, chitosan
(CS) is a natural cationic polysaccharide which is rich in its source. It has many
unique physicochemical properties, good biocompatibility, and satisfactory biode-
gradability. CS has been a popular biomaterial in pharmaceutics for decades and is
widely used in drug delivery. CS contains many amino groups. The contained
positive charges can interact strongly with the negatively charged mucosa mem-
branes, thereby facilitating CS adsorption on the mucosal surface, avoiding clear-
ance by the cilia, and improving the adhesion and penetration rate on the cell
membrane. Moreover, studies have shown that CS could open cell tight junctions,
which would promote drug transportation across the epithelial tissue. Thus, CS is an
especially suitable material for PDDS. In this chapter, we will focus on the research
progress and the applications of CS in PDDS. Many representative and advanced
studies on CS-based PDDS are reviewed in detail.
Keywords: chitosan, pulmonary drug delivery, microsphere, nanoparticle,
liposome, targeted delivery
1. Introduction
In recent decades, with the continuous development of medical technology,
people have achieved an in-depth understanding of lung functions and characteris-
tics. Pulmonary administration has been recognized as a simple and effective
method for treating lung and other diseases [1–3]. The drug delivery system (DDS),
which transports drugs directly to the lung to produce local or systemic therapeutic
effects, is known as the pulmonary drug delivery system (PDDS). Oral drugs need
to be absorbed by the gastrointestinal tract and further transported through the
blood circulation to reach the lesion site. In this series of complex processes, serious
drug loss happens after confronting acid, alkali, enzyme degradation, and liver
elimination. Ultimately, only a small amount of drugs can reach the lesion site,
which seriously reduces the drug bioavailability and impairs the therapeutic out-
comes [4]. Parenteral administration can cause damage to the tissue and reduce
patient compliance. By contrast, PDDS can deliver the drugs directly to the lung
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through the trachea for the local treatment of lung diseases. Compared with sys-
temic administration, pulmonary administration is an ideal way for treating lung
disease. It can significantly reduce the dosage, and decrease the drug distribution in
nontarget tissues, thereby reducing the toxicity and side effects [5]. After adminis-
tration through the lung, the drugs can be transported into the systemic circulation
through the thin alveolar epithelial cell layer. Thus, PDDS can also be used for
systemic drug delivery. Due to the large absorption area of the lung and the lack of
degrading enzymes, pulmonary administration can be used as a convenient and
effective noninjection administration method for biomacromolecular drugs, such as
proteins and nucleic acids [6–8]. The PDDS can maintain local drug concentration,
reduce systemic side effects, control drug release, promote drug absorption, pro-
long the drug action time, and improve patient compliance. Therefore, PDDS has
become a hotspot to prevent and treat diseases in current research [9, 10].
Chitosan (CS) is a natural and widely available polycationic polysaccharide, and
it has many unique physicochemical properties, good biocompatibility, and satis-
factory biodegradability [11]. CS has been a popular biomaterial in pharmaceutical
research for decades and is widely used in drug delivery [12]. As a drug carrier, CS
can control drug release and improve the dissolution of poorly soluble drugs. A large
number of studies have reported the developments and applications of CS-based
materials as drug delivery carriers with versatile functions, such as CS-based beads,
films, sponges, hydrogels, microspheres, and nanoparticles (NPs) [13]. Moreover,
CS contains a large number of positively charged amino groups. These positive
charges can interact strongly with the negatively charged mucosa membranes and
adsorb on the mucosal surface, thereby avoiding the drugs being removed by the
cilia, improving the adhesion rate, reducing drug clearance, and providing condi-
tions for the drugs to penetrate through the cell membrane. At the same time,
studies have shown that CS can open the tight junctions between the cells, which
will promote drug transportation through the epithelial tissues, and increase the
drug absorption rate and bioavailability [14]. Thus, CS is a suitable material espe-
cially for PDDS.
In this chapter, we focus on the applications of CS in pulmonary drug delivery.
The research progress of PDDS and the applications of CS in PDDS are reviewed,
and many representative and advanced studies on CS-based PDDS are enumerated
in detail.
2. The research progress of PDDS
2.1 The physiological basis of pulmonary administration
Lung is the respiratory organ of the human body. It cooperates with the trachea
to constitute the main place for gas exchange. The bronchi and lung can provide a
large absorption area for drugs, and the total number of human alveoli is as high as
5.6  108, and the total surface absorption area can reach up to 140 m2 [15].
Moreover, the distance from the alveoli surface to the capillaries is only about 1 μm.
By contrast, the distance is about 40 μm from the microvilli of the small intestine
mucosa to the capillaries. Therefore, the transport distance required for the pulmo-
nary absorption process is much shorter than that of intestinal absorption, and the
drugs can be rapidly absorbed through pulmonary administration. At the same
time, the lung contains the most abundant capillaries compared with other organs
in human, and about 90% of the alveolar area is covered with capillaries. The area of
pulmonary capillaries in adults can be as wide as 80 m2. Moreover, the volume of
blood flowing through the lung is very high, as almost all of the blood discharged
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from the right ventricle will pass through the lung, which is up to 5 L per minute.
This blood flow volume is the equivalent of the total blood flow in all other organs
and tissues of the body [16]. Besides, the chemical and enzymatic degradation
activity in the lung is relatively low, which can reduce the hydrolysis of the bioac-
tive macromolecules, such as proteins, peptides, and nucleic acids. Thus, these
drugs can maintain a good biological activity after pulmonary administration,
which will be beneficial to improve the drug bioavailability.
In summary, the huge absorption area, abundant capillaries, and minimal trans-
port distance together contribute to the rapid absorption of pulmonary administra-
tion. After being quickly absorbed in the lung, the drugs will directly enter the
systemic blood circulation, avoiding the first-pass effect of the liver, which is
beneficial to improve the bioavailability of the drugs. And due to the low enzyme
activity in the lung, the drug’s adverse reactions during local administration can be
reduced, which is especially suitable for the patients who need long-term adminis-
tration of the medicine [17–19].
2.2 The characteristic and development of pulmonary administration
Pulmonary administration has been initially used to relax the tracheal smooth
muscles to treat the acute exacerbation of asthma, and the disease is treated by
inhaling the drugs through the trachea and the lung in the forms of drug aerosol
particles or dry powder particles [20]. In general, there are two therapeutic pur-
poses for pulmonary administration. One is the treatment of diseases in the lung,
such as bronchial asthma and chronic obstructive pulmonary disease. The other
purpose is to achieve systemic treatment through the pulmonary absorption of the
drugs. Pulmonary inhalation administration can deliver the therapeutic agents
directly to the lesion site, which can reduce the drug distribution in nontarget
tissues. Therefore, for the treatment of pulmonary diseases, inhalation administra-
tion has a higher therapeutic index and fewer side effects than oral administration.
And pulmonary inhalation is the preferred administration method for bronchodila-
tors, β2-receptor agonists and corticosteroids [21].
With the deep understanding of lung functions and lung diseases in medicine
field, pulmonary inhalation is recognized as a simple and effective administration
route for the respiratory tract and other disease treatments. The types of the pulmo-
nary inhalation-treated diseases have been gradually increasing, such as the insulin
aerosol for treating diabetes, and the salmon calcitonin powder for the treatment of
osteoporosis and osteoarthritis [22]. In recent years, the number of studies on pul-
monary inhalation of macromolecular drugs, such as proteins and peptides, has been
increasing. These macromolecular drugs (such as insulin, growth hormone, vaccines,
and cytokines) can be formulated into pulmonary administration preparations for
local or systemic treatment. However, most of the pulmonary inhalation drugs cur-
rently used in clinical treatment is short-acting preparations, which require frequent
administrations (about 3–4 times a day). Therefore, the long-acting preparations
should be developed, because they can maintain stable blood concentrations and also
increase the compliance of the patients [23]. At the same time, the sustained or
controlled drug release preparations for pulmonary administration can effectively
regulate drug release behavior and promote drug absorption rate, thereby contribut-
ing to the achievement of ideal therapeutic effects [10].
The particle size of the pulmonary inhalation preparations directly affects the
deposition form and deposition site in the lung [24–26]. The particles of sizes
>5.0 μm produce inertial impact and are deposited in the pharynx, larynx, and
upper respiratory tract. Particles of sizes 1.0–5.0 μmmainly reach the deep part of
the respiratory tract, trachea, bronchi, and alveolar surface by gravity deposition.
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The particles of sizes 0.5–1.0 μm are deposited on the respiratory bronchioles and
alveolar walls. The particles of sizes <0.5 μm will be discharged out with airflow
due to the Brownian motion, and typically 80% of them will be expelled out of the
respiratory tract. Therefore, the particles with a size range of 1.0–5.0 μm have the
highest deposition rate in the bronchioles and alveoli, and they are generally
selected as the main components of the pulmonary inhalation preparations. Studies
have shown that the pulmonary absorption of the drugs is a passive process, a small
molecular weight contributes to fast drug absorption, and the absorption of the
macromolecular drug is relatively slow [16]. The drugs with molecular weight
below 1000 Da present short absorption half-life and good bioavailability. As the
alveolar wall is very thin, macromolecular drugs can also be absorbed through the
large gap between the cells or be swallowed into the lymphatic system by the
macrophages in alveoli, before finally entering the blood circulation [27].
In recent years, with the development of biomaterial science, biotechnology, and
medical technology, the research of new PDDS for drug-loading has focused on
polymer-based microspheres, liposomes, and NPs, which can be inhaled into the
lung and deposited in the lung mucosa through atomization and in the form of dry
powder or other forms [28]. Compared with the atomized injections currently used
in clinic, the pulmonary administration preparations based on new PDDS have the
advantages of convenience, sustained or controlled drug release, prolonged drug
action time, enhanced bioavailability, and improved therapeutic efficiency. PDDS
with better efficacy will be designed with the development of new materials and the
advancement of pharmaceutical preparation technologies. Pulmonary administra-
tion will have broad prospects for disease treatment in the medical field.
3. The applications of CS in PDDS
3.1 The basic properties of CS
CS is a nontoxic natural polymer that is the only basic polysaccharide found in
nature. It has good physical and chemical properties. CS has many advantages, such
as widely available, nontoxic, biocompatible, biodegradable, and structure modifi-
able, and its derivatives also have some unique properties. CS has been widely used
in environmental engineering, textile industry, papermaking, food industry, cos-
metics, medicine, biotechnology, pharmacy, and also many other fields [29, 30]. In
recent years, with the rapid development of the advanced DDS, CS and its deriva-
tives have received extensive attention as drug carrier materials, especially for
sustained and controlled drug release, and they have become popular research
topics in this field [31, 32].
As a drug carrier, CS has the following advantages compared with other mate-
rials. (1) CS contains a large amount of amino groups, which easily become posi-
tively charged via combination with the H+ in solution. Thus, CS has a strong
adsorption effect on carrying drugs with different characteristics [33, 34]. (2) The
polysaccharide chain of the CS and the lipopolysaccharide (LPS) structure can be
recognized by the macrophages, thereby activating and triggering local immune
responses and enhancing the targeting effect to specific tissues or cells [35]. (3) CS
and its derivatives have good antibacterial activity and can inhibit the growth and
reproduction of some fungi, bacteria, and viruses [36]. (4) CS is a polycation, which
can easily interact with the negatively charged groups on the cell membrane sur-
face, thereby changing the fluidity and permeability of the cell membrane [37]. (5)
CS is especially suitable for local administration because of its good adhesion prop-
erty and histocompatibility, which can particularly meet the requirements for drug
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retention after mucosal administration [38]. Therefore, CS has a wide range of
applications in drug delivery. It can increase the stability of the drug, prolong the
drug action time, change the administration route, increase the targeting ability of
the drug, control the drug release, improve the dissolution of drugs with poor
solubility, and adjust the cell membrane permeability of the hydrophobic drugs. At
the same time, the positively charged CS can be easily adsorbed on the mucosal
surface and also hard to be removed by the cilium, thereby providing conditions for
the drug to penetrate the cell membrane. Moreover, CS can open the tight junctions
between the cells, which will promote drug transportation in the epithelial tissues
and increase the drug absorption rate and bioavailability. Thus, CS is especially
applicable for PDDS [39, 40]. CS also has inherent immunogenicity, which is absent
in other polymers, and this enables its use as an adjuvant for vaccine delivery into
the lung [5]. Therefore, research on the applications of the CS-based PDDS has
attracted great attention all over the world.
3.2 Novel PDDS based on CS and its derivatives
Traditional pulmonary administration preparations have drawbacks such as rel-
atively short drug onset time, high frequency of administration, and poor patient
compliance. In order to overcome these problems, research has been focused on the
development of new PDDS with sustained or controlled drug release properties,
also with active targeting abilities, for increasing the drug retention time in the
lung, improving the drug concentration in treated areas, reducing the damage to
normal tissues or cells, and enhancing the bioavailability of the drugs. The new
formulations for PDDS in recent studies mainly include microspheres, polymeric
NPs, liposomes, and active targeted systems [41]. In the following content, we will
introduce the above-mentioned formulations one by one.
3.2.1 CS-based microspheres
Microspheres are microparticulate disperse systems formed by drugs dispersed
or adsorbed in the polymer matrix. Microspheres have some unique advantages as a
DDS for pulmonary administration [42]. They can be deposited in the lung, delay
the drug release, and protect biomacromolecules, such as proteins and peptides
from hydrolysis by enzymes. By optimization of the preparation process, a micro-
sphere with an aerodynamic diameter of 1–5 μm and with suitable shape and
porosity can be obtained, for meeting the requirements of pulmonary administra-
tion. In addition, microspheres usually have good stability with high moisture
resistance ability. These characteristics have determined the wide applications of
microspheres in pulmonary administration formulations [43].
There are many kinds of carrier materials for preparing microspheres. At pre-
sent, the use of biodegradable microsphere as controlled release carrier is popular in
DDS research [44]. Poly(lactic-co-glycolic acid) copolymer (PLGA) and CS are the
commonly used biodegradable materials for microsphere preparation [45]. The
conventional methods for preparing CS microspheres include emulsion
crosslinking, solvent evaporation, ion induction, and spray drying [46–49]. Among
these, crosslinking is the most commonly used method in the preparation of drug-
loaded CS microspheres with controlled-release property. The reaction can be car-
ried out under mild conditions, and it also can be industrially prepared easily [50].
Moreover, as CS is positively charged, it can combine with the negatively charged
drugs by electrostatic binding interaction to form a complex, which can help to
improve the drug loading capacity of the microspheres.
5
Applications of Chitosan in Pulmonary Drug Delivery
DOI: http://dx.doi.org/10.5772/intechopen.87932
Weifen Zhang’s group had developed a series of CS-based microspheres for
pulmonary administration. They reported the preparation of CS and β-cyclodextrin
microspheres as PDDS [51–55]. The microspheres were prepared by the spray dry-
ing method, and theophylline was loaded into the microspheres as a model drug.
These microspheres possessed spherical shape with smooth or wrinkled surfaces,
and had suitable aerodynamic diameters, which were suitable for inhalation. The
microspheres had high drug entrapment and encapsulation efficiency. They can
remain stable under storage conditions. The microspheres could also easily pene-
trate the membrane with a high permeation rate. The results showed that these
microspheres had good potential as a sustained drug release carrier for pulmonary
administration.
In Weifen Zhang’s another work, paclitaxel (PTX) and quercetin (QUE) were
respectively loaded in the NPs, which were synthesized with the oleic acid-
conjugated CS (OA-CTS). And these drug-loaded NPs were further used in the
preparation of polymeric microspheres (PMs) by the spray-drying method
(Figure 1) [56]. The microspheres could help prolong the retention time of PTX in
the presence of QUE, for bypassing the P-glycoprotein drug efflux pumps. The
diameters of the PMs ranged from 1 to 5 μm, and they had a uniform size distribution.
The PMs displayed slow-release characteristics at pH levels of 4.5 and 7.4. In vivo
pharmacokinetic and biodistribution studies suggested that the PMs exhibited a
prolonged circulation time and a markedly high accumulation in the lung. The PMs
could serve as a promising PDDS for combined therapy using hydrophobic drugs.
Recently, Ludmylla Cunha et al. developed inhalable CS microparticles for
simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment [57].
Spray-dried CS microparticles were obtained with adequate flow properties for
deep lung delivery (aerodynamic diameter of 4 μm) and high drug association
efficiencies (93% for isoniazid and 99% for rifabutin). No cytotoxicity effect was
found in human alveolar epithelial (A549) cells. The CS microparticles could acti-
vate macrophage-like cells, inducing cytokine secretion well above basal levels.
Moreover, the uptake level of macrophages to internalize microparticles was over
90%. The microparticles also inhibited bacterial growth by 96%, demonstrating that
the microencapsulation preserved drug antibacterial activity in vitro. The dual
drug-loaded CS microparticles demonstrated to be potential candidates for
inhalable therapy of pulmonary tuberculosis.
3.2.2 CS-based NPs
As a potential DDS, NPs have been widely used in medicine and other fields, and
it has already become a research hotspot for decades [58–60]. NPs can improve the
solubility and stability of the drugs, prolong the half-life, and enhance the drug
absorption rate. NPs can also help to realize sustained or controlled drug release,
prolong drug acting time, reduce administration frequency, and improve patient
compliance. Moreover, NPs can target the drugs to specific organs and cells by the
passive or active targeting ability of the multiple functionalized NPs. The NPs can
be modified to avoid the phagocytosis of the macrophages or the removal of
mucosal cilia, thereby improving the bioavailability of the drugs.
Drug delivery by NPs is an effective approach for the pulmonary administration
of insoluble drugs [61, 62]. The surface of the NPs can be modified to prolong the
drug residence time in the lung and to achieve appropriate release property for
improving the therapeutic effect. The pulmonary administration route for NPs is
mostly by inhalation in the form of aerosolized colloidal solution. However, when
the NPs are administered directly into the lung, some of them may be discharged
out with the breath due to their small particle size, thereby resulting in low
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deposition in the lung and discounted effect. Studies have shown that coating the
surface of the NPs with biocompatible polymers, such as CS, can prolong the
residence time of NPs in the lung [5]. Sometimes the surface energy of the NPs is
Figure 1.
(A) The synthesis and preparation route of the PMs. (B and C) SEM image of the PMs with a scale bar of 5 and
2 μm. (D and E) The concentration of PTX and QUE accumulated in different organs measured by HPLC at
0.5, 1, 3, and 6 h after pulmonary administration.
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relatively high, and the weak stability will lead to aggregations and interactions
between the NPs. Thus, special surface modification will also be an effective way to
improve the stability of the NPs.
Kenneth A. Howard et al. had developed CS-based siRNA-loaded NPs for pulmo-
nary RNA interference therapy [63]. The negatively charged siRNA was complexed
by the positively charged CS to form the polyelectrolyte complex NPs. The particle
size ranged from 40 to 600 nm. These NPs showed a rapid uptake (1 h) into NIH 3T3
cells. The NPs could mediate efficient knockdown of endogenous enhanced green
fluorescent protein (EGFP) in both H1299 human lung carcinoma cells and murine
peritoneal macrophages in vitro. Moreover, effective in vivo RNA interference was
also realized in the bronchiole epithelial cells of transgenic EGFP mice after nasal
administration. The results indicated that this kind of CS-based complex NPs has
great potential in RNA interference therapy for systemic and mucosal disease.
A series of CS/fucoidan (CS/F) NPs had been designed and prepared as PDDS
for gentamicin (GM) in Yi-Cheng Huang’s study (Figure 2) [64]. The NPs
presented a biphasic release feature, with a zero-order release of GM for the first
10 h, followed by a sustained release of up to 72 h, and the cumulative release value
reached 99%. The GM-loaded CS/F NPs exhibited multiple antimicrobial capabili-
ties against Klebsiella pneumoniae. The intratracheal administration of the GM-
loaded CS/F NPs displayed a higher area under the curve (AUC) and lower mini-
mum inhibitory concentration ratio than the free GM that was administrated by
intravenous injection. These results had showed that the CS/F NPs had superior
antimicrobial efficacy and lower risk of systemic toxicity, and this GM pulmonary
delivery system has exhibited good potential for pneumonia treatment.
Figure 2.
(A) The preparation of the GM-loaded CS/F NPs. (B) TEM of the GM-C5F1 NPs. (C–E) Long-term stability
of the series of CS/F NPs.
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Abdallah Makhlof et al. synthesized a thiomer derivative of glycol CS (GCS),
which was coupled with thioglycolic acid (TGA) [65]. The NPs were prepared with
GCS and GCS-TGA by ionic gelation for the pulmonary delivery of peptides. The
NPs were positively charged and had sizes in the range of 230–330 nm. They also
showed high calcitonin entrapment. After intratracheal administration, the
mucoadhesion capacity of the GCS-TGA NPs was much better than that of
nonthiolated NPs in rats. The toxic effect of the NPs with lung tissue was confirmed
with negligible epithelial damage and toxicity. The NPs could enhance the pulmo-
nary absorption of the delivered peptides, and the calcitonin-loaded GCS and GCS-
TGA NPs showed efficient hypocalcemic effect. The GCS and its thiomer derivative
could be used as potential PDDS for delivering peptides.
In another work, Adriana Trapani et al. had prepared CS and GCS NPs
containing Lipoid S100 for the systemic delivery of low molecular weight heparin
(LMWH) by pulmonary administration [66]. The NPs were prepared by ionotropic
gelation method. The NPs were positively charged and with nanoscale size. Efficient
drug entrapment and good mucoadhesive property could be achieved by using
these NPs. The LMWH was effectively delivered into the lung by the aerosolization
of the drug-loaded NPs. These results revealed the promising characteristics of the
CS-based NPs, which were highly applicable for PDDS.
Tejal Rawal et al. designed a NP-based dry powder formulation of rifampicin
(RFM) for achieving local and sustained targeting of anti-tubercular drugs to
reduce dose and frequency [67]. The drug-loaded NPs were formulated by the ionic
gelation probe sonication method. The optimized formulation had a small particle
size of 124.1 nm with an entrapment efficiency of 72%. No toxicity was found by
in vitro and in vivo experiments. The pharmacokinetic assay verified that the NP
formulation would serve a better alternative because it could minimize the frequent
dosing schedule than conventional dry powder inhalation and market formulation.
The RFM-loaded NPs open new avenues for developing therapeutic interventions
for lung tuberculosis.
3.2.3 CS-modified liposomes
Liposomes are primarily used as PDDS for the treatment of respiratory distress
syndrome and other lung diseases [68]. The drugs carried by liposomes mainly have
stable physicochemical properties and strong lipophilicity. Liposome-based drug
carrier has been one of the research hotspots in pharmaceutics [69, 70]. At present,
drug-loaded liposome preparations, such as for amphotericin B, daunorubicin,
doxorubicin, cytarabine, and morphine, have been successively developed [71]. The
liposome preparations of these drugs have many unique advantages compared with
their common preparations. Liposome-based pulmonary administration has the
advantages of rapid absorption, little irritation, good tolerance, high safety, con-
trollable drug release, and improved bioavailability [72]. The encapsulation of the
drug in liposomes affects the pharmacokinetic property of the drug and prolongs
drug half-life. Moreover, 85% of the components of the alveolar surface are phos-
pholipids, which can facilitate the liposomes accumulate and enter the lung tissue.
Liposome-loaded macromolecules with low lipophilicity can significantly improve
bioavailability, and liposomes can also reduce the side effects of the toxic drugs to
normal tissues by pulmonary administration.
Marco Zaru et al. prepared CS-coated liposomes and used them as drug carriers
for pulmonary delivery by nebulization [73]. Rifampicin (RFM) was loaded in the
CS-coated liposomes with different lipid compositions. By coating with CS, the
encapsulation efficiency of the liposomes increased slightly, and after nebulization,
the stability also remarkably increased. The mucoadhesive capacity of the
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CS-coated liposomes was much better than that of the noncoated ones. The cyto-
toxicity of the RFM-loaded CS-coated liposomes on A549 cells was much lower than
that of the free drug. The results showed that the CS coating could significantly
enhance the mucoadhesive capacity of the liposomes, and these CS-coated
liposomes could be potential drug carriers for pulmonary administration by
nebulization.
In another study, Mitsutaka Murata et al. investigated the surface modification
of liposomes by CS for pulmonary delivery [74]. The surface of the liposomes was
modified with CS oligosaccharide (oligoCS) and polyvinyl alcohol with a hydro-
phobic anchor (PVA-R). The association study showed that the PVA-R modification
decreased the interaction between liposomes and A549 cells. By contrast, the
oligoCS modification could significantly promote the cellular interaction. After
pulmonary administration to rats, the peptide elcatonin (eCT) loaded oligoCS or
PVA-R modified liposomes exhibited significantly enhanced therapeutic efficacy.
The oligoCS-modified liposomes could adhere to the lung tissues and open the tight
junctions between cells, which remarkably improved the drug absorption rate. On
the other hand, the PVA-R-modified liposomes could induce a sustained absorption
through the long-term eCT retention in lung fluid. The results verified that the
surface-modification of liposomes with oligoCS and PVA-R could be used as effec-
tive PDDS for peptide pulmonary administration.
3.2.4 CS-based active targeting DDS
The pulmonary inhalation preparations are usually directly transported into the
lung. Thus, they can passively target to the lung tissues by pulmonary administration.
The deposition site of the drugs in the lung can be controlled by regulating the
physicochemical and functional properties of the drug carriers to meet the disease
treatment requirements. In addition to passive targeting, active targeting systems
have more applications in precise and efficient disease treatment. Active targeting
systems utilize ligands or antibody-modified carriers to deliver the drugs to the
specifically targeted tissues or cells, even intracellular organelles, thereby improving
drug efficacy and reducing toxicity and side effects [75, 76]. The drug carriers could
be chemically modified with active ligands, such as sugar moieties (galactose, man-
nose, and glucose) or specific ligands, such as folic acid (FA), transferrin (Tf), and
Arg-Gly-Asp (RGD) peptide [77–79]. Antibody-mediated active targeting is also a
primary strategy for delivering the drugs to the specific parts of the body [80].
Hu-Lin Jiang et al. had prepared a folate-CS-graft-polyethylenimine (FC-g-PEI)
copolymer for cancer cell-targeting gene delivery [81]. FC-g-PEI could effectively
load and protect the shRNA. The copolymer also showed decreased cytotoxicity
compared with the PEI control. Compared with the untargeted polymer, FC-g-PEI
was a more efficient Akt1 shRNA carrier, and it exhibited effective cancer cell-
targeting ability. Moreover, aerosol delivery of the FC-g-PEI/Akt1 shRNA NPs
effectively inhibited lung tumorigenesis in the urethane-induced lung cancer model
mice via Akt signaling pathway. The results demonstrated that the FC-g-PEI could
be applied for the shRNA gene therapy via aerosol delivery.
Yongfeng Luo et al. developed an inhalable β2-adrenoceptor ligand-directed
guanidinylated-CS (GCS) carrier for targeted lung delivery of siRNA [82]. GCS
could effectively condense the siRNA and form complex NPs. Compared with
pristine CS, the siRNA-loaded GCS NPs exhibited lower cytotoxicity and higher
cellular internalization, which finally resulted in promoted gene silence efficiency.
Salbutamol (a β2-adrenoceptor agonist) was further chemically coupled to the GCS
to enhance the targeting specificity of the siRNA-loaded NPs. The gene silence
efficacy was remarkably increased both in vitro and in vivo. The carrier could
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protect the siRNA against the destructive shear forces generated by mesh-based
nebulizers. Aerosol treatment also improved the size distribution of the NPs, which
was beneficial in promoting the transfection efficiency. This CS-based targeting
DDS had potential applications for siRNA delivery in lung disease treatment by
aerosol inhalation.
Suhui Ni et al. had prepared γ-aminobutyric acid type B (GABAB) receptor
ligand-directed NPs for survivin siRNA delivery [83]. The NPs were synthesized by
baclofen (Bac)-functionalized trimethyl CS (Bac-TMC) with tripolyphosphate
(TPP) as an ionic crosslinker. GABAB receptor agonist Bac was initially introduced
into TMC as a novel ligand. The Bac-TMC/TPP NPs could promote the cellular
uptake of siRNA by interacting with the GABAB receptor, which further induced
effective gene silence and cell apoptosis. Mannitol microparticles were further
utilized for the pulmonary delivery of the siRNA-loaded NPs via pressurized
metered dose inhalers (pMDI). The obtained formulation had good aerodynamic
properties, which benefited the deep lung deposition. The pMDI formulation
containing Bac-TMC/TPP NPs could be a potential PDDS for siRNA.
Recently, Ting Wu et al. had developed a genipin-crosslinked carboxymethyl CS
nanogel for lung-targeted delivery of isoniazid (INH) and rifampin (RMP) [84].
The dual drug-loaded nanogel particles (NGPs) had a uniform particle size from 60
to 130 nm with spherical morphology. The NGPs had sustained release behavior in
simulated lung fluid. The dual drug-loaded NGPs had high antibacterial activity
against multidrug-resistantMycobacterium tuberculosis, and also could realize long-
term antibacterial activity. Further in vivo evaluation exhibited that alveolar deliv-
ery of NGPs had satisfactory deposition of drug within the lung with lower toxicity.
The results indicated that the NGPs would be a potential dosage form for treating
against multidrug-resistantMycobacterium tuberculosis.
4. Future perspectives
Pulmonary administration is a promising route for drug delivery to prevent and
treat diseases, especially for delivering the drugs for lung diseases and some small
molecule drugs with low absorption rate when in oral dosage form, also suitable for
some traditional Chinese medicines and peptide or protein drugs. PDDS can effec-
tively deliver the therapeutic drugs to the target sites, and improve the drug bio-
availability and therapeutic efficacy. Inhalation is a noninvasive method for
pulmonary administration, and the inhaled drugs can directly enter the blood cir-
culation through the absorption of the alveolar epithelium. Pulmonary administra-
tion can enhance the drug absorption rate, reduce systemic side-effects, and
improve the compliance of long-term medication. By transforming the drugs into
dry powder inhalation formulations, drug degradation can be avoided. The thera-
peutic effect of the PDDS is mainly influenced by the physicochemical properties of
the DDS, the dosage forms, and the administration devices, and also some other
factors. The increase of the amount of drug delivered into the lung and the promo-
tion of drug absorption rate are the key factors to improve the therapeutic effi-
ciency of pulmonary administration. The application of sustained or controlled
release preparations is an important method to prolong drug action time, enhance
drug bioavailability, and improve patient compliance. In recent years, many con-
trolled release preparations or active targeting preparations for pulmonary drug
delivery have been constructed by drug-loaded microparticles, liposomes, and NPs.
These multifunctional drug carriers have gained increasing popularity in pulmonary
administration. It is really inspiring for us to see that some of the PDDS have
already been applied to treat patients in clinic and become commercially available
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commodities with promising prospects. And in the coming years, great progress will
be made in PDDS research by the development of drug delivery devices and phar-
maceutical preparation technology.
The PDDS constructed with biomaterials has been a hot research direction in
medicine and pharmacy fields for decades. Among these biomaterials, CS, which is
the only natural cationic polysaccharide, has been recognized as one of the most
versatile and promising functional biomaterials. Moreover, CS is also one of the most
abundant regeneration resources, second only to the cellulose. After decades of
research, CS has been recognized as a nontoxic, biocompatible (especially with respi-
ratory cells) and biodegradable polymer. Moreover, CS can accommodate both
hydrophilic and hydrophobic drugs due to its amphiphilic properties [5]. The excel-
lent performances of CS as a building component of DDS have been confirmed by
many studies, and it has been identified as a novel drug delivery carrier with broad
application prospects, especially for sustained and controlled drug release. Due to the
unique features, CS can assist the drugs accomplishing local and systemic delivery,
realizing high mucoadhesion, and efficient drug absorption in target tissues, which is
especially applicative for PDDS. However, CS is insoluble in aqueous solutions at
neutral and alkaline pH, and it only can be dissolved in aqueous acidic media (pH
< 5). This frustrating issue has badly limited CS’s application range, and there is an
urgent need for developing convenient and practical modification strategies to
improve its solubility. Up to now, CS has been approved as safe by US-FDA and EU
for dietary use and wound dressing applications [85]. And additionally, CS has only
been approved by the European Pharmacopeia as a pharmaceutical excipient for oral
preparations. The safety issues of CS and its derivatives in pulmonary delivery and
other administration routes have not been fully understood and still remain to be
further evaluated. Therefore, the safety issue is a noteworthy research gap remained
to be filled in the future work, for figuring out the potential adverse effects of CS and
its derivatives in humans. At the same time, appropriate engineering of designing and
modifying CS and its derivatives is highly demanded to optimize the performance of
the CS-based drug carriers, for meeting the special requirements of in vivo pulmo-
nary drug delivery. We hope that in the near future, more advanced synthesis and
modification methods will be developed. And in the meanwhile, the physicochemical
property, toxicity, biodistribution, biocompatibility, and biodegradability of CS and
its derivatives should also be thoroughly investigated in detail.
5. Conclusions
Despite all this, CS-based PDDS has already achieved considerable success in the
past decades. It is believed that in the near future, with the rapid development of
material science, biotechnology, genetic engineering, medical technology, and other
scientific fields, people will have a more extensive and in-depth understanding of
the unique properties of CS and its derivatives. We hope that more efficient CS-
based PDDS will be designed, by developing novel material preparation strategies,
advanced formulation methods, and improved inhalation technology. We believe
that CS-based PDDS will play more important roles in the applications of local and
systemic disease treatment in the near future.
12
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